Whole body physiologically based pharmacokinetic (PBPK) models have been increasingly applied in drug development to describe kinetic events of therapeutic agents in animals and humans. The advantage of such modelling is the ability to incorporate vast amounts of physiological information, such as organ blood flow and volume, to ensure that the model is as close to reality as possible.
Introduction
Whole body physiologically based pharmacokinetic (PBPK) models have been broadly used in the drug development process to describe the kinetics of therapeutic agents in animals, humans and the translation of pharmacokinetics (PK) between species (Theil et al., 2003; Zhao et al., 2011; Leong et al., 2012; Johnson and Rostami-Hodjegan, 2011 , Huang and Rowland, 2012 , Barrett et al., 2012 . The development of such a modelling approach is a mechanistically driven, systems-based approach for integrating various in vitro, in silico and preclinical drugspecific data. A number of investigational new drug (IND) and (new drug application (NDA) submissions including PBPK modelling were reviewed by the Food and Drug Administration (FDA) between 2008 and 2013, and it was concluded that PBPK modelling offers advantages over the traditional population-PK compartmental approach (Zhao et al., 2011; Wagner et al., 2015) . It can be used to predict PK behaviour in humans from non-clinical data or when one drug is co-administered with other drugs, as well as to extrapolate between populations, such as from adults to paediatrics. The approach can be used to facilitate both candidate selection and during drug development. The FDA clinical pharmacology office evaluated the effectiveness of PBPK modelling in dose finding in submissions of four paediatric drugs and three marketed drugs and concluded that such an approach presented significant benefits over allometric scaling (Leong et al., 2012) .
The concept of a PBPK model is to mimic the actual physiology of an animal/human body. The model describes the dynamic and interconnecting relationships of tissues/organs (e.g. brain, heart, lung and blood vessels) using compartmental modelling techniques. It allows the incorporation of system-specific parameters such as tissue volume, blood flow, organ composition and abundance of enzymes as well as drug specific parameters such as physiochemical properties, intrinsic clearance, tissue affinity and membrane permeability of the drug. The advantage of including prior information, including physiological parameters into a common mammalian structural model, is that it ensures that the model represents the physical system. PBPK models generally sit between complex system biology models, which require in-depth details of enzyme and metabolic pathways, and the traditional data-driven multi-compartmental models frequently employed in population pharmacokinetics. The view taken is that studies in preclinical species allow detailed exploration and validation of various components of the model and methodologies, which then facilitate improved confidence in the prediction of events in human, where invariably observations are limited primarily to events in plasma and excreta.
A critical component of a PBPK model is tissue distribution, not only to define individual tissue profiles but also for ensuring mass balance. Experimentally acquiring such information is very demanding, poses ethical issues and is rarely undertaken during drug development. Nonetheless, without such information progress is limited. Accordingly, in recent years, a concerted effort has been made in gaining this information, primarily in rats, which has allowed the development of mechanistic models, based on tissue composition and physicochemical properties of a compound, to predict tissue distribution [in the form of the tissue-to-plasma concentration ratio, Kp = tissue concentration/plasma (Rodgers and Rowland, 2007; Poulin and Theil, 2009 ). Some of the groundwork for these mechanistic tissue distribution models is based on a detailed study of the tissue distribution of a series of clinically used β-blockers, basic compounds that differ widely in physicochemical and pharmacokinetic properties, possess at least one chiral centre (to explore stereochemical aspects) and are predominantly ionized at physiological pH, features in common with many cardiovascular and CNS acting compounds. In addition, there is a large body of pharmacokinetic and ADME data in the human and rat (Clark, 1982; Meier, 1982; Cruickshank and Pritchard, 1994; Mehvar and Brocks, 2001) . Previous work on this β-blocker series focussed on the estimation of Kp values determined under steady-state conditions following constant rate infusion and the application of such values to the PBPK prediction of events following bolus dose administration, which implicitly assumes that tissue distribution is perfusion rate-limited for all tissues. The objective of the current study was to evaluate this assumption experimentally and through PBPK modelling of the individual tissue concentration-time profiles and, globally, of this series in rat following i.v. bolus dose administration. Specific compounds administered were racemic acebutolol, betaxolol, bisoprolol, metoprolol, oxprenolol, pindolol and propranolol, together with S-timolol, with measurements made using enantiospecific assays.
Methods

Surgical procedures
Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . All in-life phases of this research were in compliance with UK Home Office procedures and complied with ARRIVE guidelines (http://onlinelibrary.wiley.com/doi/10. 1111/bph.12955/epdf) and the University of Manchester's policy on the use of animals in research (http://documents. manchester.ac.uk/display.aspx?DocID=18548). Indwelling cannulae were surgically inserted into the carotid artery and jugular vein of 80 male Sprague Dawley rats (approximately 250 g) under halothane anaesthesia (induction on halothane was between 3 and 4% and running on 2 -3% depending on requirement). In brief, this procedure utilized the Covance infusion harness ™ to protect the cannulae and a swivel device with lever arm, which permitted free movement of unrestrained animals throughout dose administration and blood sampling, resulting in reduced stress (Rodgers et al., 2005) .
Compounds were infused at a constant rate over 2 min into the jugular vein and blood samples withdrawn from the carotid artery.
Dose administration
The drugs were administered in cassette dose format to greatly reduce the number of animals, time, cost and labour. In previous studies (Rodgers et al., 2005) , the selected β-blockers were split into two dose cassettes, but in light of the dose levels required for this study, the compounds were divided into three dose cassettes to avoid formulation issues and adverse pharmacological events. One additional advantage is that it reduces, to some extent, interindividual variation. The first cassette (DC1) comprised racemic metoprolol (MET), oxprenolol (OXP) and propranolol (PRO) each at a dose of 1.5 mg enantiomer (free base) kg À1 . The second Riddell et al. (1987) . b Taken from Haeusler et al. (1986) . c Taken from Schoenwald and Huang (1983) , Taylor et al. (1985) , and Wang et al. (1995) . d Values calculated from the pKa and reported LogP using the Henderson-Hasselbach equation with the exception of bisoprolol where the converse procedure (LogP from reported LogD) was adopted.
Table 3
Physiological parameter values for a 250 g standard weight rat
Blood flow (mL·min À1 ) (Kuwahira et al., 1994) Volume (mL) (Igari et al., 1983) Arterial ( Total liver blood flow is the sum of flow to hepatic artery and gut. 
Sample collection
Optimum sampling times were selected using D-optimal design, a process that utilized PBPK modelling using prior knowledge of the steady-state Kp and clearance parameters (Rodgers et al., 2005; Gueorguieva et al., 2006) . At each selected time, four animals were killed. Times selected for DC1 and DC3 were 2, 5, 10, 30, 100 and 300 min, and for DC2, these were 2, 4, 10, 30, 45, 60, 100 and 300 min after the start of the infusion. At each time-point, blood (up to 0.5 mL) was sampled via the carotid artery cannula into heparin-containing tubes. Animals were then killed by cervical dislocation, and adipose, bone, brain, heart, gastrointestinal tract and stomach (combined and including contents), kidney, liver, lung, muscle, skin, testes and thymus were excised as quickly as possible. Excess blood was removed with water and tissue was blotted dry. The liver was removed first then immediately flash-frozen in liquid nitrogen to stop enzymatic reactions. For animals killed at 300 min, urine was collected over the entire study period (by means of Metabowls®) over dry ice and combined with the contents of the bladder removed during necropsy to allow for the estimation of renal clearance (CL R ).
Arterial blood was additionally sampled intermittently between the start of the infusion and the time of killing for all animals to accurately reflect the time course of the β-blockers in the systemic circulation for each animal. The resultant time points for blood collection for the combined rat population were 1, 2, 3. 5, 5, 7.5, 10, 15, 20, 25, 30, 40, 60, 80, 100, 140, 180, 220, 260 and 300 min after the start of dose infusion for DC1 and DC3 and, for DC2, were 1, 2, 4, 7, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 60, 80, 100, 140, 180, 220, 260 and 300 min after the start of dose infusion.
Sample analysis
For terminal blood samples, duplicate portions were taken for quantification, and for intermittent samples, a single aliquot was taken. For animals with terminal time points of 100 and 300 min, residual blood was pooled across all times (intermittent and terminal) by animal and dose cassette for the determination of blood-to-plasma ratios and plasma protein binding.
After removing duplicate portions of blood from the final pooled samples for quantification, the haematocrit was determined and plasma generated by centrifugation of the residual blood (2000 g, room temperature, 20 min), and duplicate aliquots were removed for determining the blood-to-plasma concentration ratio (R). To assess fraction unbound (fu), plasma water was generated by ultrafiltration of the residual plasma using Amicon Centrifree® filters (1500 g, room temperature, 20 min). Sample pretreatment, extraction and quantification of the β-blockers in the tissues and blood were as described previously (Rodgers et al., 2005) .
Experimental parameters and arterial blood population analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
The blood-to-plasma concentration ratio (R) and the fraction of drug unbound in blood (fu b = fu/R) determined from the pooled blood and plasma samples experimentally using standard equations (Rowland and Tozer, 2011) are presented in Table 1 . Some physico-chemical data of the β-blockers are shown in Table 2 .
The arterial blood concentration-time data for all animals in the temporal study were modelled using NONMEM, version 7 (Beal et al. 1989 (Beal et al. -2006 , to provide population estimates of systemic clearance (CL). A two-compartment model with i.v. input over 2 min was found adequate for all β-blockers. The model was parameterized in terms of CL, the inter-compartment clearance (CL D ) and volumes of distribution of the central compartment (V 1 ) and peripheral compartment (V 2 ). The subroutine ADVAN4 and TRANS4 were used for model description.
The fraction of each β-blocker renally excreted unchanged (fe) was calculated for each animal with a terminal time point of 300 min, long enough to ensure a reliable estimate based on preliminary i.v. pharmacokinetic information of the compounds. This together with the estimated CL in the same animal provided an estimate of CL R . The mean fe for each enantiomer along with the population estimates of CL was then used to provide population estimates of CL R and hepatic clearance (CL H ), assuming that all non-CL R is due to hepatic elimination. Intrinsic renal and hepatic clearances (CL R,int , CL H,int ), parameters in the PBPK model, were then calculated from the respective organ blood clearances and the renal and hepatic blood flows using standard equations (Rowland and Tozer, 2011) . Initial estimates of blood Kp (Kp b ) values were determined by dividing the previously reported steady-state plasma Kp values (Rodgers et al., 2005) by the value of R determined during this temporal study. 
Development of PBPK model
Open-loop modelling. Open-loop modelling, often termed as a forcing function approach (Foster, 1998) , was used to analyse data for each of the tissues and both enantiomers of each β-blocker separately. The arterial fitted profile was used as a forcing function for open-loop modelling to estimate the tissue-to-plasma partition coefficient (Kp) values. This type of modelling can be applied to all tissues, except the lung, as this tissue receives the mixed venous supply and not the arterial blood. The model building assumption is that a tissue can be either perfusion-or permeability ratelimited in nature. With perfusion rate limitation, a tissue is represented by a single well-stirred compartment where distribution into the tissue is limited by blood flow to the tissue rather than penetration of the tissue membrane. In the case of permeability-limited distribution, passage across the tissue membrane becomes the rate-limiting step in the distribution process, and a two-compartment model is used to represent this situation (Kawai et al., 1994) . The perfusion model is nested within the permeability model. For very high permeabilities, the two-compartment tissue model collapses to a one-compartment perfusion model. Openloop modelling was used as an initial step for the identification of the rate-limiting step. The Kps for the kidney and liver were corrected for extraction by those organs, as described in Rodgers et al. (2005) .
Closed-loop PBPK modelling with prior information. The openloop method relies on the forcing function being a valid input to the particular tissue, whereas the closed-loop method allows full interaction of all the tissues and blood flows of the model to come to bear on the description of that specific tissue. Open-loop estimates for all the Figure 3 Comparison of Kp values between the steady-state experiment and closed-loop modelling for all the β-blockers in each tissue. (Rodgers et al., 2005) . In addition, by using the informative PRIOR subroutine in NONMEM, the Kp (and SEM) estimates obtained from the open-loop approach were used as the prior mean Kp (and SD, taken as twice the SEM) in the closed-loop model (Langdon et al., 2007) . All tissue Kps of a compound for each enantiomer were subsequently estimated simultaneously.
Materials
Racemic acebutolol, oxprenolol and pindolol as the hydrochloride salts, metoprolol as the (+)-tartrate salt, pindolol as the free base and S-enantiomer of timolol as its maleate were purchased from Sigma & Aldrich Chemical Company (Poole, Dorset, UK). Betaxolol and bisoprolol racemates were obtained as hydrochloride and hemifumarate salts, respectively, from Tocris Cookson (Bristol, UK), along with the hydrochloride salt of R-propranolol. General-purpose reagents were generally of analytical grade and obtained from BDH (Poole, Dorset, UK) 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
Experimentally determined parameters such as fraction unbound in blood (fu b ) and blood-to-plasma concentration ratio, along with the population-estimated clearance, based on fitting the arterial blood concentration data, are presented in Table 1 for all the β-blockers.
The individual tissue distribution model of each compound was identified via the open-loop method using as the initial estimate the previously determined steady-state Kp (Kp ss ) (Rodgers et al., 2005) . The resulting open-loop Kp (Kp OL ) estimates are shown in Table 4 . This resulted in four types of structural PBPK model: where all tissues are perfusion rate limited ( Figure 1A) ; all tissues are perfusion rate limited with the exception of the gut, which is permeability rate limited ( Figure 1B) ; all tissues are perfusion rate limited except the testes, which is permeability rate limited ( Figure 1C) ; and finally, where all tissues are perfusion rate limited except both the gut and testes, which are permeability rate limited ( Figure 1D ). Table 5 shows the PBPK model that was identified for each of the β-blocker enantiomers. Although for many of the enantiomers the tissue distribution models are different, the enantiomers of acebutalol, betaxolol, bisoprolol and metoprolol have the same tissue distribution models and hence shared the same PBPK model structure. These models were then used in the closed-loop method.
All tissue Kps for a compound for each enantiomer were subsequently estimated simultaneously within the closed PBPK model, and these values are presented in Table 6 . The differences in the estimated Kp values obtained from the open and closed-loop fits are shown in Figure 2 . In general, there is good agreement between the two methods, although up to a threefold difference in the estimates between the methods was seen in some cases. Figure 3 shows a comparison of the estimated Kp values between the previous steady-state experiment (Rodgers et al., 2005) and closed-loop PBPK modelling of the iv bolus data for all the β-blockers. The Kp values of each β-blocker are plotted for each tissue. As shown, there is generally good agreement 
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for most tissues between the two estimates of Kp. Tissues such as thymus, gut and brain have similar values. Closed-loop Kp estimates tended to be higher than the steady-state Kps for liver, testes, bone and skin and tended to be lower than the steadystate Kps for adipose, muscle and kidney. These differences were generally between twofold and fourfold. Figure 4A , B illustrates the importance of using an open-loop modelling approach to determine the appropriate model to characterize the distribution kinetics of the compounds in the individual tissues. As seen in Figure 4A , the perfusion rate-limited model failed to capture the observed data for Sacebutolol in testes. In addition, in attempting to obtain an estimate of Kp, it failed to converge. As seen in Figure 4A , the fit of the permeability rate-limited model is much better, especially in the terminal slope, which also holds when undertaking closed-loop modelling. A similar picture is seen for R-bisoprolol in gut in Figure 4B . However, even though the permeability-limited model describes the data better, it does not completely describe the profile of R-bisoprolol in the gut. Figure 5A -I shows representative plots in different tissues for several of the compounds. Although there are differences between the Kps obtained from the steady-state and closed-loop methods, the closed-loop model gave good fits to the i.v. bolus data.
Open-loop fits
Closed-loop fits
Open-loop modelling helps in the development of a closed-loop PBPK model to decide whether certain tissues are perfusion or permeability rate limited. Although a closed-loop model is constructed based on the results obtained from the shape of the curve in the model and the estimated Kps from the open-loop model, it does not guarantee that a good fit will be obtained for all tissues in the closedloop model. In some cases, under or over prediction might occur. In the case of R-metoprolol, both arterial blood and testes are over predicted, as seen in Figure 6A , B respectively. From inspection of the closed-loop curve fit for the testes, one would conclude that the tissue distribution model was wrong. However, from the plot in Figure 6C , it can be seen that a good fit is obtained using open-loop modelling.
Different PBPK models when enantiomers are fitted in parallel
In the analysis above, all the β-blockers were fitted individually, although one might reasonably assume that the resultant structural model would be identical within each enantiomeric pair. However, whereas four out of seven pairs shared a common structure (R-, S-acebutolol, R-, S-betaxolol, R-, S-bisoprolol and R-, S-metoprolol), the remaining three pairs (R-, S-oxprenolol, R-, S-pindolol and R-, S-propranolol) had different structural models (Table 5) open-loop estimates for the individual enantiomers. The procedure was then repeated operating in the closed-loop mode. The compound racemic acebutolol is used here as an example to illustrate the procedures that were applied to other compounds, where the enantiomers shared a common model in which for racemic acebutolol, the gut and testes are both permeability rate limited. Table 7 lists all the tissue Kp values obtained from different methods applied to R-and S-acebutalol using single compound and pooled compound data. It is evident that the parameter estimates using the different methods agreed with each other apart from a few outlier tissues including gut and skin.
Discussion
The present work builds on experimental and theoretical studies centred on a series of benzodiazepines (Gueorguieva et al., 2004) , with emphasis on the development of a formal generic PBPK methodology and issues surrounding estimation of tissue-to-plasma concentration partition coefficients (Kps) in individual tissues from in vivo data. Benzodiazepines are very weak bases that exist predominantly unionized at physiological pH. In the current study, the range of compounds has been broadened to β-blockers as these represent a much wider class of drugs, bases predominantly ionized at physiological pH and possessing a chiral centre.
The PBPK model used in this study, and by many others, has been shown to be globally uniquely identifiable in the case where all tissue Kps, with or without intrinsic clearance, are unknown parameters to be estimated from tissue concentration data (Cheung et al., 2005) . Consequently, any differences between the various modelling methodologies are due to the assumptions of the methodology and/or the data.
Previous tissue distribution studies with the β-blocker series have been confined primarily to events at steady state in rat following constant rate infusion (Rodgers et al., 2005) . The current study extends the investigation to events following intravenous bolus dose administration, recognizing that discrete administration is the norm and that steady-state properties may not predict temporal events in all tissues, which is one of the main intended applications of PBPK modelling and simulation. The work involved determining the time course of the compounds in tissues and blood, followed by modelling the data initially in the open-loop mode and finally in the closed-loop mode.
The combination of the three drug cassettes and the corresponding estimated optimal sampling times, based on D-optimality for a multiple response system (Gueorguieva et al., 2006) , are a compromise between the wish to limit the number of animals used (recognizing that the method is destructive, with each animal providing one time point) and the desire to estimate with reasonable precision the value of Kp for all the compounds and tissues. In our previous study, to ascertain the influence of cassette dosing on the overall pharmacokinetic behaviour of the test compounds, bolus doses of the drugs were administered singularly and in cassette format via the jugular vein. Clearance and volume of distribution values were calculated from plasma data, and values were similar for both dose modalities, indicating drug-drug interactions and adverse pharmacological events were not an issue for the compound cassettes selected for this study (Rodgers et al., 2005) . The PBPK model applied in the design assumed that distribution for all compounds and tissues is perfusion rate limited. As it relates to estimation of Kp the design worked reasonably well in most cases. However, an additional objective of the current temporal study was to evaluate whether distribution was perfusion or permeability rate limited, noting that it always takes longer to reach distribution equilibrium when a permeability limitation prevails than expected based on assuming a perfusion rate limitation. We observed that the perfusion-limited model did not fit the data well for gut and testes for some compounds and so investigated permeability-limited models for these tissues only. In these experiments, the earliest possible sampling time was 1 min after drug administration, yet even by this time, it was calculated that some tissues may equilibrate so rapidly as to make it difficult to distinguish between a permeability and perfusion limitation. It was anticipated that this problem would arise when the anticipated half-life for distribution is less than 0.3 min, in which case equilibrium is achieved by approximately 1 min. Under perfusion-limited conditions, the half-life for distribution is given by 0.693*Kp/(Q/V T ), where V T is the volume of the tissue, and Q/V T is the relative tissue perfusion rate. Applying this relationship to the corresponding values for Q, V (Table 3) and Kp ss (Table 1) , this condition (t 1/2 < 0.3 min) is met for 11% of the 180 tissue-drug combinations, of which not unexpectedly approximately two-thirds applied to lung and the remainder comprised acebutolol distributing into brain and pindolol distributing into a variety of tissues, due to a combination of low Kp and relatively high perfusion. Thus, apart from these situations, it was considered that a permeability rate limitation would be detected if it occurred, as indeed was the case for some compounds and tissues (see below). For some β-blockers, modelling each enantiomer individually resulted in the apparent need for differences in certain parts of the structural model, whereas modelling both enantiomers simultaneously allowed stabilization of parameter estimation and robust identification of the PBPK model structure (Cheung et al., 2009) .
A comparison of steady-state and temporal data-based closed-loop fits has shown that significantly different Kp estimates can be the result. However, there are no clear trends except that tissues that exhibit permeability-limited kinetics tended to yield higher closed-loop Kp estimates than the steady-state values. Furthermore, it was found that in some cases, enantiomers did not share the same tissue distribution model for some tissues, even though it was expected.
It is clear that some tissues are more challenging to model, especially the gut and kidney, than others owing to the presence of secreted compound in the luminal fluids, which are not strictly a part of the respective tissue. For the permeability model for gut and testes, we assumed two-compartment kinetics separating the vascular and extra-vascular spaces in each of these tissues, on the assumption that the permeability barrier is at the vascular endothelium. However, during the experimental study, the measured concentration in gut comprised tissue plus luminal content, which may well contain gastric-secreted compound, due to the pH gradient between acidic stomach and near neutral plasma (Shore et al., 1957) , together with biliary (Piquette-Miller and Jamali, 1997) or intestinally (Terao et al., 1996) secreted compound for some of β-blockers. A similar problem arises in the case of the kidney owing to the presence of compound in the lumen of the nephron, via filtration and in some cases secretion, some or the majority of which may be reabsorbed and therefore not strictly a component of the affinity for renal tissue, as conveyed in the model for this organ. The identifiability of more complex models than considered so far would have to be addressed before proceeding to parameter estimation in such cases.
With the exception of the testes and the gut, the assumption of one-compartment perfusion rate-limited tissue model holds for all tissues and compounds studied, which is a common assumption in many existing PBPK simulations of Figure 7 (A, B) Closed-loop fits to (A) arterial and (B) muscle data for Sbetaxolol with blood flow for muscle set at the literature value of 16.3 mL·min À1 .
predicted PK of drug substances in drug discovery (Jones et al., 2012) and clinical development, especially when dealing with small lipophilic drugs (Maharaj and Edginton, 2014) . Perhaps this is not surprising for the particular β-blockers studied. These are small, reasonably lipophilic molecules (Rodgers et al., 2005) and are predominantly classified as BDDCS Class 1 compounds (Benet et al., 2011) . This class of compounds has been found to possess high permeability across many membranes and which do not appear to be influenced in their oral absorption or distribution by transporters, including the brain (Broccatelli et al., 2012) , a tissue for which perfusion rate limitation was also found in this study. This condition was clearly not met with testes or gut indicating that membrane resistance of these tissues is even higher than for the brain. The resistance of gut tissue to distribution may appear to be contrary to the high intestinal permeability of this class of compound. However, viewed from the intestinal lumen, the only barrier to absorption is the thin epithelial layer of enterocytes, which comprise a small fraction of total tissue and receives only about 8% of total intestinal blood flow. Whereas distribution into gut tissue from blood involves the entire tissue, including muscle layers, lamina propria, serosa and nerves, in addition to the epithelial layer. It is to these additional intestinal components that the resistance may well lie. Alternatively, the permeability rate limitation for gut is more apparent than real, based on the comment above that assayed gut comprised both gut tissue and luminal contents. In such a case, an alternative model, comprising gut tissue, for which distribution is perfusion rate limited, linked reversibly with gut luminal contents and, assayed together, can be seen to be isomorphic with the initially postulated model. It is of note that the compounds for which distribution into testes was found to be perfusion rate limited, that is, propranolol, betaxolol, metoprolol and oxprenolol, are the most lipophilic compounds within the current series, based on logP, although it is appreciated that additional factors, such as degree of ionization, plasma protein binding and bloodto-plasma ratio, also can influence the kinetics of tissue distribution. The logP values for these four compounds ranged from 3.84 for propranolol to 1.88 for metoprolol, compared to values between 1.48 and 1.83 for the rest of the studied compounds (Benet et al., 2011; Hosey et al., 2016) .
Bisoprolol, which behaved similarly to the bulk of the series, with perfusion rate-limited distribution into all tissues but testes, is classified as a BDDCS Class 3 compound (highly soluble and predominantly renally excreted unchanged; Benet et al., 2011) , with an expectation that transporters would be important, at least in their intestinal absorption. Certainly, there is evidence that some β-blockers within the series studied, such as pindolol, are substrates of the renal transporter OCT2 (Dudley et al., 2000) . In the case of the more polar β-blockers, such as atenolol, nadolol and talinolol (which were not part of the current study), all BDDCS Class 3 drugs, transporter involvement in permeation of some cell membranes has been shown (Ciarimboli and Schlatter, 2005) . In passing, it is worth noting that the fraction eliminated unchanged (one of the criteria used in the BDDCS classification) can vary with the species studied. For example, the fraction renally excreted unchanged for bisoprolol and pindolol is 65 and 54%, respectively, in human (Benet et al., 2011) , compared to just 11 and 5.3% in rat (Table 1) .
Clearly, while the slow distribution of most of the β-blockers into testes, and perhaps gut, may be relevant if these tissues are sites of action or toxicity, the impact on the drug profile in systemically circulating blood or other tissues is negligible, given their small volumes (1 and 5% body weight, respectively, Table 3 ) and that Kp values of the drugs in testes are about average compared to all other tissues.
A poor closed-loop fit to the arterial and muscle concentration-time data for S-betaxolol is observed and shown in Figure 7 . The mechanism of action of β-blockers is to decrease arterial blood pressure by reducing cardiac output, which might reduce the blood flow to the muscle. To test this hypothesis, the data were refitted with varying muscle blood flow rates from 16.3 reducing to 8 mL·min À1 , achieved by proportionally decreasing cardiac output and assuming no change in the fractional split to all other tissues. This resulted Figure 8 (A, B) Closed-loop fits to arterial and muscle data for S-betaxolol with blood flow varying from 8 to 16.3 mL·min À1 (literature value).
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in a small but significant improvement in the goodness of fit to arterial blood data for lower blood flow rates, especially in early time points up to 100 min, shown in Figure 8 , but no real improvement to the fit of the model to the muscle data. Accordingly, this avenue was not pursued further for any other compound studied. Fitting of these models to the sparse data is taxing to say the least. Since the tissues are being fitted simultaneously, the model will compromise different tissues to get the overall best fit, in this case based on maximum likelihood. So some tissues will be over-predicted and some under-predicted. Weighting some tissues more heavily than others might help but would have to be justified.
Conclusion
Various closed-loop PBPK models were developed for enantiomers of a series of racemic β-blockers, namely, acebutolol, betaxolol, bisoprolol, metoprolol, oxprenolol, pindolol and propranolol, together with S-timolol following i.v. bolus administration to rats. Individual tissue distribution of each of the compounds was first tested based on the results of openloop forcing function modelling. For most compounds and tissues, distribution kinetics was adequately defined by a one-compartment perfusion rate-limited model, as expected for such small lipophilic molecules. Evidence of a permeability rate limitation was found however for some compounds in the testes (and perhaps gut). When the enantiomers were fitted individually, sometimes, different distribution models for the testes and gut compartments were needed. It had been thought that this could be due to the experimental procedure, in that, for example, gut tissues were collected and assayed as a single tissue, whereas it comprises a mixture of tissues, whose permeabilities may be perfusion-or membrane rate-limiting. Fitting racemic pairs simultaneously overcame this problem, yielding a common tissue model structure. Parameter estimates of the tissue-to-blood partition coefficient from steady-state experiments, individually and in racemic pairs, were mostly in agreement. The objective function (OF) obtained from the paired estimation was equal to the sum of the OFs obtained for the pairs estimated individually. This indicates that the population behaviour for each of the racemic pairs is the same and that they have the same structure. However, when the data were pooled together to gain a common structure, there was no reduction in the value of OF, as both sets of data are required to define the common structure to filter out any experimental bias. Although simultaneous fitting of racemate kinetics allows stabilization of parameter estimates and robust identification of PBPK model structure, this forced the enantiomers of compounds such as propranolol and pindolol to have similar Kp values. In reality, these compounds should have different Kps due to the differences in fu of the enantiomers of these two compound and, therefore, simultaneous PBPK modelling for R-S racemate kinetics, which assumed common Kps, should only be performed when the fu of the two enantiomers are similar. PBPK modelling is a very powerful tool to aid drug discovery and development of therapeutic agents in animals and humans. However, careful consideration of the assumptions made during the modelling exercise is essential.
